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Introduction 
An important result of the continuing follow-up and 
analysis of the German 2 2 4 Ra patients is the nearly 
equal sensitivity of the juvenile and the adult pa-
tients to bone-sarcoma induction. This conclusion 
has been obtained from a competing risk corrected 
determination of the cumulative tumor rates [ 5 , 7 ] . 
The present study extends the analysis in terms of 
the proportional hazards model. 
Analysis in Terms of the 
Proportional Hazards Model 
The analysis is based on the continuing follow-up 
of the patients up to June 1984 [6] , with only minor 
changes compared to the earlier published listing 
[11]. Of the total of 899 patients, the 38 with 
unknown doses (6 with bone sarcomas) were ex-
cluded from the analysis. Of the 53 patients that 
incurred bone sarcomas two patients developed an 
additional bone sarcoma, believed to be a new 
primary tumor and therefore included in the analy-
sis. The diagram of Figure 1 represents all patients 
in terms of their estimated average skeletal dose 
[ 12] and their age at the beginning of the treatment. 
The diagram demonstrates the inverse correlation 
between age at treatment and average skeletal dose. 
It also shows the high bone-sarcoma frequencies at 
high doses. 
Figure 1 does not contain some essential addi-
tional information, such as the time at risk for the 
individual patients. It also does not give the dura-
tions of treatment which vary substantially and tend 
to increase with increasing dose. The time at risk is 
taken into account in the subsequent analysis, but 
possible dose-rate effects are not assessed. 
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Fig. 1: Distribution of ages of the 
2 2 4Ra patients at the beginning of 
treatment and of mean skeletal doses. 
Each symbol represents a patient. 
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Table 1. Dose Classes for the Non-Parametric Analysis 
Group Dose Mean Skeletal Dose Number Number Cum. Tumor 
Number Classes ± St. Dev. in Group of Patients of Bone Rate* * at 
(gray) (gray) Sarcomas t = 25 years 
Adults (Males and Females) 
1 D < 1 .58 ± .21 214 1 .0061 ± .0060 
2 1 < D < 2 1.43 ± .26 189 2 .013 ± .010 
3 2 < D < 4 2.82 ± .58 163 5 (+ Ό * .046 ± .020 
4 4 < D 5.79 ± 1.33 83 5 .072 ± .033 
Juveniles (Boys and Girls) 
5 D < 4 2.40 ± 1.1 34 I .036 ± .036 
6 4 < D < 8 5.95 ± 1.1 63 4 ( + D * .086 ± .035 
7 8 < D < 12 9.95 ± 1.1 52 8 .19 ± .06 
8 12 < D < 16 13.9 ± 1.2 30 7 .29 ± .12 
9 16 < D < 20 17.8 ± 1.0 13 7 .78 ± .30 
10 20 < D 32.5 ± 10 19 7 .67 ± .24 
v 860 49 
* double bone sarcoma 
** from the proportional hazards analysis 
Non-Parametric Analysis 
In an extension of the earlier analysis that corrected 
for competing risks [5] juvenile and adult patients 
were subdivided into several dose groups (Tab. 1). 
For the individual groups of patients separate esti­
mates of the cumulative tumor rate, R(t), were then 
derived in their dependence on time, t, after treat­
ment. The sum-limit estimate [4, 5] is used for this 
purpose. 
The resulting curves are represented in Figure 2. 
They show a consistent trend with mean skeletal 
dose. For easier readability of the graphs the stan­
dard deviations are not indicated; as to be expected 
with the relatively small number of tumors per 
group, they are substantial. The difference between 
groups 9 and 10 is not significant. The data indicate 
the general trend of the bone-sarcoma rates. But the 
separate estimates are not very suitable to derive the 
dose dependence quantitatively. A more sophisti­
cated approach is, therefore, required, and the 
apparent absence of any variations of the latency 
period suggests that the familiar proportional 
hazards model [3] is most suitable for the analysis. 
Fig. 2: Cumulative tumor rates cal­
culated from the sum-limit estimate 
for the dose groups specified in 
Table 1. 
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The essential assumption of this model is that the 
tumor rates (hazard functions) after treatment - and 
therefore also the cumulative tumor rates - are the 
same for all dose groups, except for a factor that 
depends on dose. This is expressed by the equation: 
R ( t , D ) = ß(D)Ro( t ) (1) 
R 0 (t) , the so-called base-line function, is a depend-
ence on time that is not a priori specified; (3(D) is a 
function of absorbed dose or mean absorbed dose. 
An analysis in terms of this model is called non-
parametric, i f no analytical expressions are post-
ulated for the form of the two functions R 0(t) and 
ß ( D ) . The algorithm [3] developed from earlier 
results of Cox [1] determines those two relations 
that fit the data best in the sense of maximum 
likelihood. In the analysis with separate dose 
groups one obtains values of the function ß ( D ) only 
for the average skeletal doses assigned to the 
groups. 
The proportional hazards analysis has, in a first 
step, been performed separately for the juvenile 
patients and the adult patients. The results are given 
as plain lines in the two panels of Fig. 3. Compar-
ing the curves in the two panels one notes that the 
dependences are similar for those two pairs of dose 
groups of juveniles and adults that have roughly the 
same average skeletal dose (groups 3 vs. 5 and 4 vs. 
6). As a next step the analysis has therefore been 
performed jointly for all 10 groups; i.e. identity of 
the base-line function, R 0(t) has been postulated for 
juveniles and adults, and the optimal shape of this 
function and optimal values of the proportional 
hazards coefficients, ßj (i = 1 to 10), have been 
obtained. The results, which are given by the lines 
with dots in the panels of Fig. 3, are in striking 
agreement with the data from the separate analysis. 
There is, from the separate analysis, no indication 
of a difference in the time course of the bone-
sarcoma rates between the groups of juvenile and 
adult patients. The influence of the differing skelet-
al dose is expressed merely in the factors ßj for the 
various groups (i = 1 to 10). These values are 
proportional to the numbers in the last column of 
Table 1. 
The points in Fig. 4 give the total bone-sarcoma 
risk divided by the mean skeletal dose for the 
different dose groups of juvenile and adult patients. 
The risk equals the cumulative tumor rate reached 
at the end of the expression period at t = 25 years. 
The standard errors are obtained by a bootstrap 
method, i.e. by random simulations of the distribu-
tion of bone sarcomas into the different dose groups 
under the assumption of the estimated values ßi. 
With this method the standard errors are derived 
from a large number of simulations with subse-
quent proportional hazards analysis. The mag-
nitude of the standard errors shows that the differ-
ence between the last two groups is not statistically 
significant. 
A linear regression for the groups below 8 Gy in 
yields the dose coefficient 0.013/Gy for the inci-
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Fig. 3: Cumulative tumor rates cal-
culated according to the proportional 
hazards model. The numbers refer to 
the groups specified in Table 1. 
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Fig. 4: Risk per person per gray vs. 
mean skeletal dose. The points with 
their standard errors result from the 
proportional hazards analysis (see 
Eq[l]) with separate dose classes. 
The solid line results from an analysis 
according to Eq(3) without formation 
of dose classes. 
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dence of bone sarcomas. However, the data points 
in Figure 4 are indicative of a dose-effect relation 
that is not linear. A further step in the analysis must 
therefore aim at the determination of the most likely 
shape of the dose-effect relation. This wi l l also bear 
on the problem of saturation at high doses. 
Parametric Analysis 
To assess a possible non-linearity in the dose-effect 
relation one must replace the non-parametric dose 
dependence of the proportional hazards coeffi­
cients, β, by a suitable analytical expression. The 
analysis aims then at the estimation of the parame­
ters in this expression. The familiar linear-quadra­
tic dose dependence with added exponential term at 
high doses is utilized: 
R(t,D) = (aD + ßD 2 ) exp ( - yD) • R 0(t) (2) 
No a priori assumption is made on the base-line 
function, R 0 ( t ) , for the time dependence of the 
cumulative tumor rate, i.e. this part of the analysis 
remains non-parametric. One determines the func-
tion and the parameters that are in best agreement 
with the entire set of data, without the need to 
establish dose groups. With this model, the numeri-
cal solution can not be based on the Cox algorithm. 
Instead another procedure is required that utilizes a 
non-linear optimization algorithm for the likeli-
hood. This is merely a technical matter that does 
not alter the essence of the approach. 
The resulting dose dependence (with D in gray): 
R(t,D) = (0.0085 D + 0.0017 D 2 ) e x p ( - 0.025 D) 
•Ro(t) (3) 
is represented in Fig. 4 (solid line) in terms of the 
total bone-sarcoma risk 25 years after treatment, 
R(25 yrs), divided by D. The base-line function, 
R 0 ( t ) , i.e. the temporal dependence of the cumula-
tive tumor rate is nearly the same as that obtained in 
the preceding non-parametric analysis; it is there-
fore not represented. The linear coefficient in the 
estimated dose relation is 0.0085/Gy, i.e. some-
what less than the value, 0.013/Gy, obtained from 
fitting a constant to the first 6 points in Figure 4. A 
linear regression to all data without formation of 
dose classes is rejected with error level ρ = 0.02; 
but i f overall linearity were postulated, the risk 
factor 0.018/Gy would be obtained. 
Control incidences have not be accounted for in 
the preceding computations. To estimate a control 
incidence we have used age dependent bone-sarco­
ma rates for West-Germany averaged over the 
calendar years 1970-1978*. Integrating these 
bone-sarcoma rates over the distribution in age of 
* Data kindly provided by Dr. Frentzel-Beyme, 
Deutsches Krebsforschungszentrum, Heidelberg. Ger­
man bone-sarcoma rates from a published compilation 
[14] lead to the same conclusions. The rates for bone 
sarcomas during the years 1970-1978 were utilized. 
They conform to the revision of the ICD (International 
Classification of Diseases) which excludes certain 
tumors, such as plasmocytomas, that were earlier 
counted among the bone sarcomas. 
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the total number of years at risk one obtains the 
value 0.0004 as the control risk for bone sarcoma 
per patient. This value is sufficiently small not to 
influence the results of the computations. There is 
no evidence that either ankylosing spondylitis [10] 
or tuberculosis [2] increase the incidence of bone 
cancer in non-irradiated patients. 
Discussion 
The competing-risk corrected analysis of the bone-
sarcoma rates in the 2 2 4 Ra patients has been carried 
further in the present investigation. The data are in 
agreement with the postulate of the proportional 
hazards model. No indication is found that supports 
the assumption of a shortening of the latency period 
with increasing doses. The results support also the 
conclusion of equal sensitivity of the juvenile and 
the adult patients. The expression period of bone 
sarcomas appears to be nearly terminated 25 years 
after the treatment; the integrated incidence per 
individual at risk during the whole expression 
period can, therefore, be given. The best estimate 
of the dose-effect relation is a linear-quadratic 
dependence according to Eq(3), as given in Figure 
4. The risk coefficient, 0.0085/Gy, obtained in this 
way for small doses is substantially smaller than the 
value 0.018/Gy which would be obtained from a 
linear regression. This linear regression without 
dose classes is rejected with error level ρ = 0.02. 
The mean skeletal dose is inversely correlated 
with age at treatment (see Fig. 1) and is correlated 
with treatment time (see Fig. 5). The nonlinearity 
of the dose-effect relation could therefore, in prin­
ciple, be due to one of the two confounding factors. 
Age at treatment appears to play no major role 
(see Fig. 3). The increased protraction times at 
higher doses, however, may influence the observed 
dose dependence. A n enhancement of the α-ray 
effectiveness due to protraction, as earlier sug­
gested by Spiess and Mays for these patients [12], 
has been demonstrated in animal experiments with 
2 2 4 Ra [9] . 
Regardless of the remaining uncertainties in the 
interpretation, the estimate on the basis of the 
linear-quadratic model seems appropriate for the 
estimation of the risk factor for small doses given 
over several weeks. In the current treatment of 
ankylosing spondylitis patients with 2 2 4 Ra the mean 
skeletal doses are about 0.56 Gy over 10 weeks 
[13]. The estimates from our analysis are applic­
able to this group. The risk factor of 0.0085/Gy for 
the induction of skeletal sarcomas w i l l , in the years 
to come, be measured against the continuing fol­
low-up of the current group of 2 2 4 Ra patients [15]. 
Summary 
Forty-nine bone sarcomas have occurred among 
861 patients injected with known amounts of 2 2 4 Ra 
corresponding to average skeletal doses from 0.06 
to 57.5 Gy. A competing risk corrected analysis of 
• BONE SARCOMA 
• NO BONE SARCOMA 
. · • • . . . ' » • ' . • 4 · * * « · · . 
10 100 
MEAN SKELETAL DOSE (Gy) 
Fig. 5: Distribution of mean skelet­
al doses and treatment times. Each 
symbol represents a patient. 
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the data in terms of the Cox proportional hazards 
model indicates equal sensitivity and equal time 
course of the bone tumor rates in juvenile and in 
adult patients at comparable mean skeletal doses. 
The proportional hazard coefficients follow a 
linear-quadratic dependence on absorbed dose, and 
the cumulative bone sarcoma risk (R) over the ex-
pression period of about 25 years is: R = (0.0085 D 
+ 0.0017 D 2 ) e x p ( - 0.025 D ) , where D is the 
mean skeletal dose in gray. A simple linear fit up to 
mean skeletal doses of 8 Gy yields the relation 
R = 0.013 D . 
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